missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ DRIL1 Polyclonal Antibody

Rabbit Polyclonal Antibody
Brand: Invitrogen™ PA552106
This item is not returnable.
View return policy
Description
Immunogen sequence: FGGSLFAYSP GGAHGMLSSP KLPVSSLGLA ASTNGSSITP APKIKKEEDS AIPITVPGRL PVSLAGHPVV AAQAAAVQAA AAQAAVAAQA AALEQLREKL ESAEPPEKKM ALVADEQQRL MQRALQQ Highest antigen sequence identity to the following orthologs: Mouse - 94%, Rat - 95%.
The mouse Bright (B-cell regulator of IgH transcription) protein is expressed specifically in B cells and transactivates an IgH enhancer in transient transfection assays. Bright and the Drosophila 'dead ringer' (dri) gene product belong to a protein family whose members share a conserved DNA-binding domain termed the 'A/T-rich interaction domain' (ARID).
Specifications
| DRIL1 | |
| Polyclonal | |
| Unconjugated | |
| ARID3A | |
| ARID domain-containing 3A; ARID domain-containing protein 3A; ARID3A; AT rich interactive domain 3A (Bright like); AT rich interactive domain 3A (BRIGHT- like) protein; AT rich interactive domain 3A (BRIGHT-like); AT-rich interaction domain 3A; AT-rich interactive domain-containing protein 3A; B-cell regulator of IgH transcription; BRIGHT; dead ringer homolog 1; dead ringer-like 1; dead ringer-like protein 1; Dri1; DRIL1; DRIL3; DRX; E2F-binding protein 1; E2FBP1 | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 1820 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
| Immunohistochemistry (Paraffin), Immunocytochemistry | |
| 0.1 mg/mL | |
| PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
| Q99856 | |
| ARID3A | |
| Recombinant protein corresponding to Human DRIL1. Recombinant protein control fragment (Product #RP-102503). | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction